{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:52:16Z","timestamp":1792212736356,"version":"4.4.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ondansetron is a selective serotonin (5HT3) receptor antagonist that is under evaluation as an adjunctive treatment for schizophrenia, and a novel treatment for hallucinations in Parkinson\u2019s disease. Ondansetron reverses sensory gating deficits and improves visuoperceptual processing in animal models of psychosis, but it is unclear to what extent preclinical findings have been replicated in humans. We systematically reviewed human studies that evaluated the effects of ondansetron and other 5HT3 receptor antagonists on sensory gating deficits or sensory processing. Of 11 eligible studies, eight included patients with schizophrenia who were chronically stable on antipsychotic medication; five measured sensory gating using the P50 suppression response to a repeated auditory stimulus; others included tests of visuoperceptual function. Three studies in healthy participants included tests of visuoperceptual and sensorimotor function. A consistent and robust finding (five studies) was that ondansetron and tropisetron (5HT3 antagonist and \u03b17-nicotinic receptor partial agonist) improved sensory gating in patients with schizophrenia. Tropisetron also improved sustained visual attention in non-smoking patients. There was inconsistent evidence of the effects of 5HT3 antagonists on other measures of sensory processing, but interpretation was limited by the small number of studies, methodological heterogeneity and the potential confounding effects of concomitant medication in patients. Despite these limitations, we found strong evidence that selective 5HT3 antagonists (with or without direct \u03b17-nicotinic partial agonist effects) improved sensory gating. Future studies should investigate how this relates to potential improvement in neurocognitive symptoms in antipsychotic naive patients with prodromal or milder symptoms, in order to understand the clinical implications.<\/jats:p>","DOI":"10.1038\/s41386-021-01255-4","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T13:02:53Z","timestamp":1641906173000},"page":"880-890","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Selective 5HT3 antagonists and sensory processing: a systematic review"],"prefix":"10.1038","volume":"47","author":[{"given":"Eirini","family":"Tsitsipa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4671-5410","authenticated-orcid":false,"given":"Jonathan","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Casalotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Belessiotis-Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Zubko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimona S.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5334-3969","authenticated-orcid":false,"given":"James A.","family":"Bisby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"1255_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejphar.2014.10.031","volume":"753","author":"B Olivier","year":"2015","unstructured":"Olivier B. Serotonin: a never-ending story. Eur J Pharm. 2015;753:2\u201318.","journal-title":"Eur J Pharm"},{"key":"1255_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4103\/0972-6748.62273","volume":"18","author":"S Kumar","year":"2009","unstructured":"Kumar S, Soren S, Chaudhury S. Hallucinations: etiology and clinical implications. Ind Psychiatry J. 2009;18:119\u201326.","journal-title":"Ind Psychiatry J."},{"key":"1255_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fncir.2018.00051","volume":"12","author":"SN Jacob","year":"2018","unstructured":"Jacob SN, Nienborg H. Monoaminergic neuromodulation of sensory processing. Front Neural Circuits. 2018;12:51.","journal-title":"Front Neural Circuits"},{"key":"1255_CR4","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1152\/jn.00034.2020","volume":"123","author":"TR Sizemore","year":"2020","unstructured":"Sizemore TR, Hurley LM, Dacks AM. Serotonergic modulation across sensory modalities. J Neurophysiol. 2020;123:2406\u201325.","journal-title":"J Neurophysiol"},{"key":"1255_CR5","doi-asserted-by":"publisher","first-page":"106S","DOI":"10.1016\/S0893-133X(99)00046-9","volume":"21","author":"HY Meltzer","year":"1999","unstructured":"Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999;21:106S\u201315S.","journal-title":"Neuropsychopharmacology"},{"key":"1255_CR6","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/npp.2009.176","volume":"35","author":"HY Meltzer","year":"2010","unstructured":"Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson\u2019s disease psychosis. Neuropsychopharmacology 2010;35:881\u201392.","journal-title":"Neuropsychopharmacology"},{"key":"1255_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014;383:533\u201340.","journal-title":"Lancet"},{"key":"1255_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.neuropharm.2008.08.003","volume":"56","author":"NM Barnes","year":"2009","unstructured":"Barnes NM, Hales TG, Lummis SC, Peters JA. The 5-HT3 receptor\u2014the relationship between structure and function. Neuropharmacology 2009;56:273\u201384.","journal-title":"Neuropharmacology"},{"key":"1255_CR9","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1124\/pr.59.07103","volume":"59","author":"KB Fink","year":"2007","unstructured":"Fink KB, Gothert M. 5-HT receptor regulation of neurotransmitter release. Pharm Rev. 2007;59:360\u2013417.","journal-title":"Pharm Rev"},{"key":"1255_CR10","doi-asserted-by":"crossref","unstructured":"De Deurwaerdere P, Di Giovanni G. Serotonergic modulation of the activity of mesencephalic dopaminergic systems: therapeutic implications. Prog Neurobiol. 2016;151:175\u20136.","DOI":"10.1016\/j.pneurobio.2016.03.004"},{"key":"1255_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuron.2016.06.033","volume":"91","author":"R Tremblay","year":"2016","unstructured":"Tremblay R, Lee S, Rudy B. GABAergic interneurons in the neocortex: from cellular properties to circuits. Neuron 2016;91:260\u201392.","journal-title":"Neuron"},{"key":"1255_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.77","volume":"5","author":"J Smucny","year":"2015","unstructured":"Smucny J, Stevens KE, Olincy A, Tregellas JR. Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation. Transl Psychiatry. 2015;5:e587.","journal-title":"Transl Psychiatry"},{"key":"1255_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.pharmthera.2006.08.004","volume":"113","author":"KD Alex","year":"2007","unstructured":"Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharm Ther. 2007;113:296\u2013320.","journal-title":"Pharm Ther"},{"key":"1255_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.brainres.2009.08.075","volume":"1300","author":"KM Wildeboer","year":"2009","unstructured":"Wildeboer KM, Zheng L, Choo KS, Stevens KE. Ondansetron results in improved auditory gating in DBA\/2 mice through a cholinergic mechanism. Brain Res. 2009;1300:41\u201350.","journal-title":"Brain Res"},{"key":"1255_CR15","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/0091-3057(90)90385-U","volume":"35","author":"JM Barnes","year":"1990","unstructured":"Barnes JM, Costall B, Coughlan J, Domeney AM, Gerrard PA, Kelly ME, et al. The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates. Pharm Biochem Behav. 1990;35:955\u201362.","journal-title":"Pharm Biochem Behav"},{"key":"1255_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00213-005-0142-0","volume":"183","author":"K Hashimoto","year":"2005","unstructured":"Hashimoto K, Iyo M, Freedman R, Stevens KE. Tropisetron improves deficient inhibitory auditory processing in DBA\/2 mice: role of alpha 7 nicotinic acetylcholine receptors. Psychopharmacology 2005;183:13\u20139.","journal-title":"Psychopharmacology"},{"key":"1255_CR17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/sj.mp.4001490","volume":"9","author":"G Rammes","year":"2004","unstructured":"Rammes G, Eisensamer B, Ferrari U, Shapa M, Gimpl G, Gilling K, et al. Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Mol Psychiatry. 2004;9:846\u201358. 18","journal-title":"Mol Psychiatry"},{"key":"1255_CR18","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.mp.4001314","volume":"8","author":"B Eisensamer","year":"2003","unstructured":"Eisensamer B, Rammes G, Gimpl G, Shapa M, Ferrari U, Hapfelmeier G, et al. Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol Psychiatry. 2003;8:994\u20131007.","journal-title":"Mol Psychiatry"},{"key":"1255_CR19","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/0140-6736(93)90327-D","volume":"341","author":"J Zoldan","year":"1993","unstructured":"Zoldan J, Friedberg G, Goldberg-Stern H, Melamed E. Ondansetron for hallucinosis in advanced Parkinson\u2019s disease. Lancet 1993;341:562\u20133.","journal-title":"Lancet"},{"key":"1255_CR20","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1212\/WNL.45.7.1305","volume":"45","author":"J Zoldan","year":"1995","unstructured":"Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson\u2019s disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995;45:1305\u20138.","journal-title":"Neurology"},{"key":"1255_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12017-013-8251-0","volume":"16","author":"T Kishi","year":"2014","unstructured":"Kishi T, Mukai T, Matsuda Y, Iwata N. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review. Neuromolecular Med. 2014;16:61\u20139.","journal-title":"Neuromolecular Med"},{"key":"1255_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jpsychires.2019.02.024","volume":"113","author":"W Zheng","year":"2019","unstructured":"Zheng W, Cai DB, Zhang QE, He J, Zhong LY, Sim K, et al. Adjunctive ondansetron for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res. 2019;113:27\u201333.","journal-title":"J Psychiatr Res"},{"key":"1255_CR23","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1177\/0269881118798608","volume":"32","author":"J Kulkarni","year":"2018","unstructured":"Kulkarni J, Thomas N, Hudaib AR, Gavrilidis E, Gurvich C. Ondansetron\u2014a promising adjunctive treatment for persistent schizophrenia. J Psychopharmacol. 2018;32:1204\u201311.","journal-title":"J Psychopharmacol"},{"key":"1255_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1176\/ajp.157.1.55","volume":"157","author":"KS Cadenhead","year":"2000","unstructured":"Cadenhead KS, Light GA, Geyer MA, Braff DL. Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. Am J Psychiatry. 2000;157:55\u20139.","journal-title":"Am J Psychiatry"},{"key":"1255_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.schres.2014.11.020","volume":"161","author":"EA Hazlett","year":"2015","unstructured":"Hazlett EA, Rothstein EG, Ferreira R, Silverman JM, Siever LJ, Olincy A. Sensory gating disturbances in the spectrum: similarities and differences in schizotypal personality disorder and schizophrenia. Schizophr Res. 2015;161:283\u201390.","journal-title":"Schizophr Res"},{"key":"1255_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1176\/appi.ajp.2017.16111203","volume":"175","author":"HK Hamilton","year":"2018","unstructured":"Hamilton HK, Williams TJ, Ventura J, Jasperse LJ, Owens EM, Miller GA, et al. Clinical and cognitive significance of auditory sensory processing deficits in schizophrenia. Am J Psychiatry. 2018;175:275\u201383.","journal-title":"Am J Psychiatry"},{"key":"1255_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10:89.","journal-title":"Syst Rev"},{"key":"1255_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1365-2753.2010.01516.x","volume":"18","author":"S Armijo-Olivo","year":"2012","unstructured":"Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. J Eval Clin Pr. 2012;18:12\u20138.","journal-title":"J Eval Clin Pr"},{"key":"1255_CR29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.schres.2008.08.004","volume":"107","author":"S Akhondzadeh","year":"2009","unstructured":"Akhondzadeh S, Mohammadi N, Noroozian M, Karamghadiri N, Ghoreishi A, Jamshidi AH, et al. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res. 2009;107:206\u201312.","journal-title":"Schizophr Res"},{"key":"1255_CR30","unstructured":"Mohammadi N, Noroozian, M, Karamghadiri, N, Akhondzadeh, S. 5Ht3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial. Basic Clin Neurosci. 2010;1:10\u201314."},{"key":"1255_CR31","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1176\/appi.ajp.2012.11081289","volume":"169","author":"XY Zhang","year":"2012","unstructured":"Zhang XY, Liu L, Liu S, Hong X, Chen DC, Xiu MH, et al. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry. 2012;169:974\u201381.","journal-title":"Am J Psychiatry"},{"key":"1255_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-9-27","volume":"9","author":"A Shiina","year":"2010","unstructured":"Shiina A, Shirayama Y, Niitsu T, Hashimoto T, Yoshida T, Hasegawa T, et al. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry. 2010;9:27.","journal-title":"Ann Gen Psychiatry"},{"key":"1255_CR33","first-page":"14","volume":"42","author":"R Samadi","year":"2017","unstructured":"Samadi R, Soluti S, Daneshmand R, Assari S, Manteghi AA. Efficacy of risperidone augmentation with ondansetron in the treatment of negative and depressive symptoms in schizophrenia: a randomized clinical trial. Iran J Med Sci. 2017;42:14\u201323.","journal-title":"Iran J Med Sci"},{"key":"1255_CR34","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/s41386-020-0685-0","volume":"45","author":"L Xia","year":"2020","unstructured":"Xia L, Liu L, Hong X, Wang D, Wei G, Wang J, et al. One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia. Neuropsychopharmacology 2020;45:1362\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"1255_CR35","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1176\/appi.ajp.162.2.386","volume":"162","author":"LE Adler","year":"2005","unstructured":"Adler LE, Cawthra EM, Donovan KA, Harris JG, Nagamoto HT, Olincy A, et al. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry. 2005;162:386\u20138.","journal-title":"Am J Psychiatry"},{"key":"1255_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/BF02244559","volume":"104","author":"ST Hall","year":"1991","unstructured":"Hall ST, Ceuppens PR. A study to evaluate the effect of ondansetron on psychomotor performance after repeated oral dosing in healthy subjects. Psychopharmacology 1991;104:86\u201390.","journal-title":"Psychopharmacology"},{"key":"1255_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1365-2125.1991.tb05537.x","volume":"31","author":"TJ Leigh","year":"1991","unstructured":"Leigh TJ, Link CG, Fell GL. Effects of granisetron and lorazepam, alone and in combination, on psychometric performance. Br J Clin Pharm. 1991;31:333\u20136.","journal-title":"Br J Clin Pharm"},{"key":"1255_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.brainresbull.2003.09.022","volume":"65","author":"Y Levkovitz","year":"2005","unstructured":"Levkovitz Y, Arnest G, Mendlovic S, Treves I, Fennig S. The effect of Ondansetron on memory in schizophrenic patients. Brain Res Bull. 2005;65:291\u20135.","journal-title":"Brain Res Bull"},{"key":"1255_CR39","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41386-018-0174-x","volume":"44","author":"ER Stern","year":"2019","unstructured":"Stern ER, Shahab R, Grimaldi SJ, Leibu E, Murrough JW, Fleysher L, et al. High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. Neuropsychopharmacology 2019;44:390\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"1255_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.schres.2004.12.016","volume":"76","author":"K Koike","year":"2005","unstructured":"Koike K, Hashimoto K, Takai N, Shimizu E, Komatsu N, Watanabe H, et al. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res. 2005;76:67\u201372.","journal-title":"Schizophr Res"},{"key":"1255_CR41","first-page":"399","volume":"85","author":"BJ Sahakian","year":"1992","unstructured":"Sahakian BJ, Owen AM. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J R Soc Med. 1992;85:399\u2013402.","journal-title":"J R Soc Med"},{"key":"1255_CR42","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","volume":"20","author":"C Randolph","year":"1998","unstructured":"Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20:310\u20139.","journal-title":"J Clin Exp Neuropsychol"},{"key":"1255_CR43","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1016\/j.neuroimage.2010.11.039","volume":"54","author":"N Bak","year":"2011","unstructured":"Bak N, Glenthoj BY, Rostrup E, Larsson HB, Oranje B. Source localization of sensory gating: a combined EEG and fMRI study in healthy volunteers. Neuroimage 2011;54:2711\u20138.","journal-title":"Neuroimage"},{"key":"1255_CR44","doi-asserted-by":"publisher","first-page":"111078","DOI":"10.1016\/j.pscychresns.2020.111078","volume":"300","author":"MI Atagun","year":"2020","unstructured":"Atagun MI, Drukker M, Hall MH, Altun IK, Tatli SZ, Guloksuz S, et al. Meta-analysis of auditory P50 sensory gating in schizophrenia and bipolar disorder. Psychiatry Res Neuroimaging. 2020;300:111078.","journal-title":"Psychiatry Res Neuroimaging"},{"key":"1255_CR45","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1093\/schbul\/sbj050","volume":"32","author":"D Potter","year":"2006","unstructured":"Potter D, Summerfelt A, Gold J, Buchanan RW. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull. 2006;32:692\u2013700.","journal-title":"Schizophr Bull"},{"key":"1255_CR46","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pscychresns.2013.07.002","volume":"214","author":"J Smucny","year":"2013","unstructured":"Smucny J, Wylie K, Rojas D, Stevens K, Olincy A, Kronberg E, et al. Evidence for gamma and beta sensory gating deficits as translational endophenotypes for schizophrenia. Psychiatry Res. 2013;214:169\u201374.","journal-title":"Psychiatry Res"},{"key":"1255_CR47","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.clinph.2013.02.004","volume":"124","author":"DM Smith","year":"2013","unstructured":"Smith DM, Grant B, Fisher DJ, Borracci G, Labelle A, Knott VJ. Auditory verbal hallucinations in schizophrenia correlate with P50 gating. Clin Neurophysiol. 2013;124:1329\u201335.","journal-title":"Clin Neurophysiol"},{"key":"1255_CR48","first-page":"1309","volume":"10","author":"P Vlcek","year":"2014","unstructured":"Vlcek P, Bob P, Raboch J. Sensory disturbances, inhibitory deficits, and the P50 wave in schizophrenia. Neuropsychiatr Dis Treat. 2014;10:1309\u201315.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1255_CR49","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/0006-8993(92)91437-J","volume":"587","author":"V Luntz-Leybman","year":"1992","unstructured":"Luntz-Leybman V, Bickford PC, Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res. 1992;587:130\u20136.","journal-title":"Brain Res"},{"key":"1255_CR50","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00213-002-1285-x","volume":"165","author":"JK Simosky","year":"2003","unstructured":"Simosky JK, Stevens KE, Adler LE, Freedman R. Clozapine improves deficient inhibitory auditory processing in DBA\/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology 2003;165:386\u201396.","journal-title":"Psychopharmacology"},{"key":"1255_CR51","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1073\/pnas.94.2.587","volume":"94","author":"R Freedman","year":"1997","unstructured":"Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA. 1997;94:587\u201392.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1255_CR52","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/oxfordjournals.schbul.a033320","volume":"24","author":"LE Adler","year":"1998","unstructured":"Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull. 1998;24:189\u2013202.","journal-title":"Schizophr Bull"},{"key":"1255_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0035-1570334","volume":"37","author":"G Lightfoot","year":"2016","unstructured":"Lightfoot G. Summary of the N1-P2 cortical auditory evoked potential to estimate the auditory threshold in adults. Semin Hear. 2016;37:1\u20138.","journal-title":"Semin Hear"},{"key":"1255_CR54","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.neuroimage.2009.06.063","volume":"48","author":"T Rosburg","year":"2009","unstructured":"Rosburg T, Trautner P, Elger CE, Kurthen M. Attention effects on sensory gating\u2014intracranial and scalp recordings. Neuroimage 2009;48:554\u201363.","journal-title":"Neuroimage"},{"key":"1255_CR55","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.neuron.2006.09.020","volume":"52","author":"PJ Uhlhaas","year":"2006","unstructured":"Uhlhaas PJ, Singer W. Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron 2006;52:155\u201368.","journal-title":"Neuron"},{"key":"1255_CR56","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.tins.2012.11.006","volume":"36","author":"M Larkum","year":"2013","unstructured":"Larkum M. A cellular mechanism for cortical associations: an organizing principle for the cerebral cortex. Trends Neurosci. 2013;36:141\u201351.","journal-title":"Trends Neurosci"},{"key":"1255_CR57","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.brainresrev.2004.08.006","volume":"48","author":"M Sarter","year":"2005","unstructured":"Sarter M, Hasselmo ME, Bruno JP, Givens B. Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Res Brain Res Rev. 2005;48:98\u2013111.","journal-title":"Brain Res Brain Res Rev"},{"key":"1255_CR58","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1523\/JNEUROSCI.20-12-04745.2000","volume":"20","author":"TM Gill","year":"2000","unstructured":"Gill TM, Sarter M, Givens B. Sustained visual attention performance-associated prefrontal neuronal activity: evidence for cholinergic modulation. J Neurosci. 2000;20:4745\u201357.","journal-title":"J Neurosci"},{"key":"1255_CR59","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/ntr\/nty034","volume":"21","author":"JR Tregellas","year":"2019","unstructured":"Tregellas JR, Wylie KP. Alpha7 nicotinic receptors as therapeutic targets in schizophrenia. Nicotine Tob Res. 2019;21:349\u201356.","journal-title":"Nicotine Tob Res"},{"key":"1255_CR60","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0896-6273(00)80380-3","volume":"19","author":"Z Gil","year":"1997","unstructured":"Gil Z, Connors BW, Amitai Y. Differential regulation of neocortical synapses by neuromodulators and activity. Neuron 1997;19:679\u201386.","journal-title":"Neuron"},{"key":"1255_CR61","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.psychres.2009.01.025","volume":"175","author":"MC Waldo","year":"2010","unstructured":"Waldo MC, Woodward L, Adler LE. Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study. Psychiatry Res. 2010;175:179\u201380.","journal-title":"Psychiatry Res"},{"key":"1255_CR62","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1038\/npp.2015.176","volume":"40","author":"RS Keefe","year":"2015","unstructured":"Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, et al. Randomized, double-blind, placebo-controlled study of encenicline, an alpha7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology 2015;40:3053\u201360.","journal-title":"Neuropsychopharmacology"},{"key":"1255_CR63","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.2174\/1381612821666150605111345","volume":"21","author":"K Hashimoto","year":"2015","unstructured":"Hashimoto K. Targeting of alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia and the use of auditory sensory gating as a translational biomarker. Curr Pharm Des. 2015;21:3797\u2013806.","journal-title":"Curr Pharm Des"},{"key":"1255_CR64","doi-asserted-by":"crossref","unstructured":"Sehatpour P, Javitt DC, De Baun HM, Carlson M, Beloborodova A, Margolin DH, et al. Mismatch negativity as an index of target engagement for excitation\/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058. Neuropsychopharmacology. 2021. (ePub ahead of print).","DOI":"10.21203\/rs.3.rs-525748\/v1"},{"key":"1255_CR65","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000087558","volume":"52","author":"K Cattapan-Ludewig","year":"2005","unstructured":"Cattapan-Ludewig K, Hilti CC, Ludewig S, Vollenweider FX, Feldon J. Rapid visual information processing in schizophrenic patients: the impact of cognitive load and duration of stimulus presentation. A pilot study. Neuropsychobiology 2005;52:130\u20134.","journal-title":"Neuropsychobiology"},{"key":"1255_CR66","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000265133","volume":"61","author":"CC Hilti","year":"2010","unstructured":"Hilti CC, Delko T, Orosz AT, Thomann K, Ludewig S, Geyer MA, et al. Sustained attention and planning deficits but intact attentional set-shifting in neuroleptic-naive first-episode schizophrenia patients. Neuropsychobiology 2010;61:79\u201386.","journal-title":"Neuropsychobiology"},{"key":"1255_CR67","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.psychres.2009.12.012","volume":"177","author":"CC Hilti","year":"2010","unstructured":"Hilti CC, Hilti LM, Heinemann D, Robbins T, Seifritz E, Cattapan-Ludewig K. Impaired performance on the Rapid Visual Information Processing task (RVIP) could be an endophenotype of schizophrenia. Psychiatry Res. 2010;177:60\u20134.","journal-title":"Psychiatry Res"},{"key":"1255_CR68","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00702-004-0169-0","volume":"111","author":"PB Forgacs","year":"2004","unstructured":"Forgacs PB, Bodis-Wollner I. Nicotinic receptors and cognition in Parkinson\u2019s disease: the importance of neuronal synchrony. J Neural Transm. 2004;111:1317\u201331.","journal-title":"J Neural Transm"},{"key":"1255_CR69","doi-asserted-by":"publisher","first-page":"e675","DOI":"10.1212\/WNL.0000000000006007","volume":"91","author":"MJ Firbank","year":"2018","unstructured":"Firbank MJ, Parikh J, Murphy N, Killen A, Allan CL, Collerton D, et al. Reduced occipital GABA in Parkinson disease with visual hallucinations. Neurology 2018;91:e675\u2013e85.","journal-title":"Neurology"},{"key":"1255_CR70","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1017\/S0140525X05000130","volume":"28","author":"D Collerton","year":"2005","unstructured":"Collerton D, Perry E, McKeith I. Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations. Behav Brain Sci. 2005;28:737\u201357.","journal-title":"Behav Brain Sci"},{"key":"1255_CR71","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/mds.20308","volume":"20","author":"NJ Diederich","year":"2005","unstructured":"Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson\u2019s disease as disturbed external\/internal perceptions: focused review and a new integrative model. Mov Disord. 2005;20:130\u201340.","journal-title":"Mov Disord"},{"key":"1255_CR72","doi-asserted-by":"publisher","first-page":"fcz007","DOI":"10.1093\/braincomms\/fcz007","volume":"1","author":"A Zarkali","year":"2019","unstructured":"Zarkali A, Adams RA, Psarras S, Leyland LA, Rees G, Weil RS. Increased weighting on prior knowledge in Lewy body-associated visual hallucinations. Brain Commun. 2019;1:fcz007.","journal-title":"Brain Commun."}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-021-01255-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-021-01255-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-021-01255-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:04:16Z","timestamp":1666310656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-021-01255-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1255"],"URL":"https:\/\/doi.org\/10.1038\/s41386-021-01255-4","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"assertion":[{"value":"16 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RSW has received speaker fees from GE Healthcare and Honoraria from Britannia. All other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}